VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Passes Below Fifty Day Moving Average - Here's Why

VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.29 and traded as low as $2.25. VistaGen Therapeutics shares last traded at $2.25, with a volume of 194,283 shares changing hands.

Analyst Upgrades and Downgrades

Separately, William Blair reaffirmed an "outperform" rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 18th.

VistaGen Therapeutics Price Performance

The stock's fifty day moving average price is $2.30 and its 200-day moving average price is $2.52. The firm has a market cap of $73.02 million, a PE ratio of -1.46 and a beta of 0.61.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its quarterly earnings data on Tuesday, June 17th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.09. VistaGen Therapeutics had a negative return on equity of 58.88% and a negative net margin of 6,777.08%. The business had revenue of ($0.01) million during the quarter, compared to analysts' expectations of $0.18 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. On average, sell-side analysts anticipate that VistaGen Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

Institutional Trading of VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTGN. Cubist Systematic Strategies LLC purchased a new stake in shares of VistaGen Therapeutics during the first quarter worth approximately $25,000. Two Sigma Advisers LP purchased a new position in shares of VistaGen Therapeutics in the 4th quarter valued at about $35,000. Man Group plc acquired a new position in VistaGen Therapeutics during the fourth quarter worth about $54,000. Bank of America Corp DE lifted its position in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock valued at $62,000 after acquiring an additional 19,331 shares during the period. Finally, Boothbay Fund Management LLC purchased a new stake in shares of VistaGen Therapeutics during the 4th quarter worth approximately $66,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.